Connect
MJA
MJA

The beginning of the end of warfarin?

John W Eikelboom and Graeme J Hankey
Med J Aust 2004; 180 (11): 549-551.
Published online: 7 June 2004

Randomised trials suggest that ximelagatran is “non-inferior” to warfarin for preventing stroke in patients with non-valvular atrial fibrillation, but important questions remain

  • John W Eikelboom1
  • Graeme J Hankey2

  • Royal Perth Hospital, Perth, WA.

Correspondence: 

Competing interests:

Graeme Hankey is a member of the Steering Committee of the AMADEUS trial, the Stroke Advisory Committee of the ACTIVE trial, and the Atrial Fibrillation Advisory Board for Exanta, AstraZeneca, Australia.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.